The susceptibility profile of 91 Sporothrix schenckii isolates in both growth phases was determined by microdilution test (Antifungal Susceptibility Testing of the European Committee for Antimicrobial Susceptibility Testing; AFST-EUCAST). Amphotericin B (AMB), itraconazole (ITC), posaconazole, ravuconazole and terbinafine were found active in vitro against both phases but minimum inhibitory concentrations values for mycelial phase were significantly higher. Fluconazole (FLC) and voriconazole (VRC) were inactive in vitro against both phases. The E-test technique was also performed with 41 representative isolates for AMB, FLC, ITC and VRC. Average agreement rates between yeast phase microdilution results and E-test results were high for AMB (77.5%) and FLC (87.8%), but low for ITC and VRC with rates of 56.4% and 54.5%, respectively. AFST-EUCAST is not the most recommended test to perform drug susceptibility testing of S. schenckii in clinical laboratories, and E-test could be an alternative methodology for this purpose, mainly when the activity in vitro of antifungal agents of AMB and FLC are evaluated.
Introduction
Sporotrichosis is a subacute or chronic subcutaneous infection caused by the dimorphic fungus Sporothrix schenckii. Itraconazole (ITC) is used in the treatment of sporotrichosis, while amphotericin B (AMB) may be indicated for extensive involvement of the disease. 1 Most studies to determine the susceptibility profile of S. schenckii to antifungal agents have used the mycelial form because colonies grow easily within a few days to 2 weeks at 25-28°C. 2, 3 However, which growth phase should be used in those methodologies is still an open question for dimorphic fungi. Based on the biological cycle of this class of fungi where filamentous phase is found in the environment, and the infective yeast phase into the host, it has been suggested, therefore, that susceptibility testing for those species such as Histoplasma capsulatum should be performed with the yeast forms. 4 Broth dilution methods seem to be the reference methodologies for those species, 2, 3, 5 but the yeast phase is difficult to test in this format. The E-test appears to be a viable and practical alternative to the reference methods for susceptibility testing of fastidious or slow growing fungus like the yeast phase of Sporothrix. However, the Etest technique has been hardly ever evaluated to test the susceptibility profile of those species. This is the largest study reported describing the antifungal susceptibilities in vitro of S. schenckii in both phases and comparing results obtained by microdilution reference methodologies with those achieved by the commercial E-test technique.
Materials and methods

Isolates
A total of 91 clinical isolates of S. schenckii were included in this study. Organisms were obtained from the collection of the Mycology Laboratory of Instituto de Pesquisa Clínica Evandro Chagas (FIOCRUZ) and from the Mycelial Collection of the Spanish National Center for Microbiology. Isolates were retrieved from storage in distilled water at a controlled temperature of 4°C, subcultured on Potato dextrose agar (PDA) plates and incubated at 25°C until adequate growth was obtained. All these isolates were identified as S. schenckii by typical colony morphology on PDA and microscopical appearance (septate hyaline hyphae, conidiophores and typical conidia). For the conversion to the yeast form, mycelial cultures grown on PDA were subcultured on brainheart infusion agar (BHI) at 35°C, and microscopical appearance of growth on culture was observed as oval to cigar-shaped yeast cells.
Antifungal susceptibility testing
Microdilution test
The susceptibility testing was performed on the 91 isolates in both yeast and mould forms following the recommendations of the European Subcommittee for Antifungal Susceptibility Testing of the European Committee for Antimicrobial Susceptibility Testing (AFST-EUCAST) with minor modifications. 6 Briefly, susceptibility testing included RPMI medium supplemented with 2% glucose as the assay medium and an inoculum size of 1 · 10 5 -5 · 10 5 CFU ml )1 . The mycelial inoculum was adjusted by microscopical enumeration with a cell-counting haematocytometer. The yeast inoculum was adjusted by a spectrophotometer at 530 nm and turbidity was measured and adjusted to match a 0.5 Mc Farland density. The microplates were incubated for 72 h (the exponential phases of S. schenckii) at 30°C for mycelial phase and at 35°C for yeast phase. Mycelial phase was tested in static incubation the preferential condition for good growth of fungi. However, yeast phase was incubated in a shaker because the aeration improve the growth of S. schenckii.
Microplates were wrapped with a film sealer to prevent the medium from evaporating and agitated at 16.4 g. Visual readings were performed with the help of a mirror. Minimum inhibitory concentrations (MIC) were defined as the lowest concentration showing complete inhibition of growth. Susceptibility test was performed in duplicate on two different days. The antifungal agents used were AMB (Sigma-Aldrich Quimica SA, Madrid, Spain), fluconazole (FLC; Pfizer SA, Madrid, Spain), ITC (Janssen Pharmaceutica, Madrid, Spain), voriconazole (VRC; Pfizer, Ltd, Sandwich, UK), ravuconazole (Bristol-Myers Squibb, Princeton, NJ, USA), posaconazole (Schering-Plough, Kenilworth, NJ, USA) and terbinafine (TRB; Novartis, Basel, Switzerland). Aspergillus fumigatus ATCC 204305 and Aspergillus flavus ATCC 204304 were included as control isolates for the mycelial phase and Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 for the yeast phase.
E-test for yeast phase
A total of 41 representative isolates converted to the yeast phase were tested. Mould phase were converted by culturing isolates on BHI agar (0.77% calf brain, 0.98% beef heart; Difco, Oxoid, Madrid, Spain) at 37°C. E-test strips with AMB, FLC, ITC and VRC were obtained from AB-Biodisk (Stockolmon, Sweden). The E-test was also performed on BHI agar and in accordance with the manufacturerÕs instructions. 7 The MIC was read after 72 h of incubation at 35°C. Because of the continuous gradient antifungal agents, the MIC endpoint was elevated to the next twofold dilutions concentration, which matched the dilution schema of the microdilution technique. Candida parapsilosis ATCC 22019 and C. krusei ATCC 6258 were used as control strains.
Analysis of results
The reproducibility between MIC values obtained against both phases and between microdilution and E-test results were calculated by determining the percentage of agreement between MIC values. Agreement was defined as discrepancies in MIC results of no more than twofold dilutions. In addition, the correlation between the results was evaluated by using the intraclass correlation coefficient (ICC), which was expressed to a maximum value of 1 and with a confidence interval of 95%. The ICC is a reverse measurement of the variability of the counting values. To approximate a normal distribution, the MICs were transformed to log 2 values. A P < 0.01 was considered with statistical significance. Statistical analysis was performed with the Statistical Package for the Social Sciences (SPSS version 15.0; SPSS S.L, Madrid, Spain).
Results
Overall, the antifungal agents tested for microdilution reference method (AFST-EUCAST) were active in vitro against S. schenckii (Table 1 ). AMB and TRB were the most active compounds in vitro and only FCL were inactive for the both phases. VRC also was inactive against a significant rate of antifungal agents. When MIC values obtained by microdilution were compared per phase, higher values were found against the mycelial phase for all antifungal agents tested apart from TRB that was more active in vitro against the mycelial than against the yeast form. Difference in MIC values between phases was up to two or three twofold dilutions and thus, agreements were high (>85%) and ICCs were statistical significant for antifungal compounds with the exception of VRC. Table 2 shows the per cent agreement rates between the MICs of the two phase within +2 dilutions.
The correlation between microdilution yeast phase and E-test results is given in Table 3 . Average agreements rates were high for AMB (77.5%) and FLC (87.8%), but low for ITC and VRC with rates of 56.4% and 54.5% respectively. MIC values of both ITC and VRC by E-test were invariably lower than those obtained by microdilution (Table 1 and Table 3 ). The ICCs between results by microdilution and E-test MIC values were significant for AMB, FLC and ITC. Minimum inhibitory concentrations values of quality control strains were in the expected quality control ranges.
Discussion
The results of this study conform to those of others showing the good susceptibility of S. schenckii to most of the antifungal agents apart form FLC and VRC. 2, 3, 5, [8] [9] [10] In general, higher MIC values were found against the mycelial phase for all antifungal agents as demonstrated in other studies. [8] [9] [10] A better understanding of what leads to the difference between the yeast and mycelial antifungal susceptibility of S. schenckii, and also which of them better reflects the therapeutic response should be investigated. However, in this study, only VRC presented different results between both phases if we look at ranges and geometric means. Kohler et al. [10] suggested that one of the possibilities for the higher MIC values of mycelial phase could be because of inoculum size. However, a same size of the inoculum (10 5 ) was utilised by us for both phases. Some other factors such as continuous shaking of S. schenckii yeast phase during 3 days because of the slow growth of fungi may have favoured media evaporation and this small change in the initial conditions could interfere in our results. Nowadays, it is not possible to determine the isolates, which are resistant or susceptible to the drugs tested because the MIC breakpoints have not been well established yet for S. schenckii. However, ÔsusceptibleÕ isolate with low MIC and ÔresistantÕ strain with relatively high MIC of determined antifungal were observed in this study. The correlation between methods to classify the strains as ÔsusceptibleÕ was very good for AMB. Also, the E-test was able to detect ÔresistanceÕ to FLC, as described in the microdilution testing as also previously reported elsewhere. 2, 8, 9 However, the use of the E-test to study the activity of ITC and VRC was not good and needs further studies. It should be noted that BHI was needed to do susceptibility testing in solid format with the yeast phase of S. schenckii and that assay medium is not completely defined in the E-test what could have significant influence on our results.
In summary, our results suggest that the conditions of growth used in the antifungal susceptibility testing for S. schenckii can influence the MIC. Mycelial phase, the non-parasitic form, showed higher MIC in vitro than the yeast phase. Susceptibility testing with S. schenckii by EUCAST method in the mycelial form is laborious and reproducible; in the yeast form, is hardly affordable for clinical laboratories because of the slow growth of the fungus. On the other hand, the E-test of S. schenckii in the yeast form could be an alternative method to determine the susceptibility of those organisms to AMB and FLC. 
